One-Dose MVA-BN Vaccine Moderately Effective Against Mpox
By Elana Gotkine HealthDay Reporter
TUESDAY, Sept. 17, 2024 -- One dose of modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is moderately effective against mpox infection in at-risk communities, according to a study published online Sept. 11 in The BMJ.
Christine Navarro, M.D., from Public Health Ontario in Toronto, and colleagues estimated the real-world effectiveness of the MVA-BN vaccine against mpox infection in an emulation of a target trial involving 9,803 men with a history of being tested for syphilis and a laboratory-confirmed bacterial sexually transmitted infection in the previous year or who filled a prescription for HIV pre-exposure prophylaxis in the previous year. Those who had been vaccinated 15 days previously were matched with unvaccinated men in a 1:1 ratio on each day between June 12 and Oct. 27, 2022. A total of 3,204 men who received the vaccine were matched with 3,204 unvaccinated controls.
The researchers identified 71 mpox infections, with 0.09 and 0.20 per 1,000 person-days in the vaccinated and unvaccinated groups, respectively, during the study period of 153 days. For one dose of MVA-BN, the estimated vaccine effectiveness against mpox infection was 58 percent.
"Our findings strengthen the evidence that MVA-BN is effective at preventing mpox infection and should be made available and accessible to communities at risk," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
COVID-19 Tied to Higher Risk for Inflammatory Diseases of the Airways
THURSDAY, Aug. 28, 2025 -- People who have had COVID-19 have an increased risk for developing certain new-onset type 2 inflammatory diseases of the airways, while receipt of a...
Tdap, MenACWY Coverage Increased in Teens From 2023 to 2024
TUESDAY, Aug. 19, 2025 -- From 2023 to 2024, coverage with one or more doses of the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) and the...
Two Doses of Zoster Vaccine Reduce Risk for Herpes Zoster Ophthalmicus
TUESDAY, Aug. 19, 2025 -- Two doses of recombinant zoster vaccine (RZV) are associated with a reduced risk for herpes zoster ophthalmicus (HZO), acute myocardial infarction, and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.